박병탁 기자

Park Pyeongtak

Reporter
Biowatch Team With a background in Business Administration (MBA), I focus on the pharmaceutical and biotech industries. My goal is to select key information and present it in an easily understandable manner.
mail ppt@kormedi.com

Latest Articles

Eli Lilly Licensing Deal Surge: Hanmi Pharmaceutical’s Q2 Operating Profit Jumps 117%

Placebo Outperforms TG-C: Data Errors and Stock Volatility Cloud Kolon TissueGene’s Phase 3 Trial

Celltrion Files for EU Approval of Cosentyx Biosimilar CT-P55, Targeting $6.7 Billion Autoimmune Market

Daewoong Pharmaceutical Cuts Off Hospital Sales After Domestic Nabota Vials Surface in the U.S.

HLB Innovation Expands Phase 1 CAR-T Trial Following Clean Early Safety Data

Samsung Biologics Posts 586.4 Billion Won Q2 Profit, But Labor Uncertainty Looms

117 Workplace Accidents Recognized at 25 Major Korean Pharma and Biotech Firms Over Five Years

Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal

Previous56789Next